Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping

首次发布于 2025 年 11 月 26 日

A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping

计划入组 70 人 · 首次发布于 2026 年 5 月 14 日

AOC-1044

Delpacibart

Delpacibart braxlosiran

Avidity Biosciences Plans BLA Submission for Delpacibart Zotadirsen in DMD44 by Late 2025

Avidity Biosciences Secures $345M Following Promising Duchenne Muscular Dystrophy Trial Results

Duchenne Muscular Dystrophy: Biotech Firms Advance Novel Therapies